Last updated: November 5, 2026
ReFacto, marketed as Xyntha in the United States, is Pfizer’s recombinant factor VIII product for hemophilia A. Its commercial position is mature and under pressure from extended-half-life factor VIII products, non-factor prophylaxis with Hemlibra, and emerging gene therapies. Pfizer does not report ReFacto or Xyntha as a standalone revenue line, so the product’s exact financial trajectory is not publicly quantifiable. The available evidence supports a declining or low-growth profile rather than a major expansion opportunity.
What is ReFacto and how does it work?
ReFacto is moroctocog alfa, a B-domain-deleted recombinant coagulation factor VIII. The product replaces deficient factor VIII in patients with hemophilia A and is used for on-demand treatment, surgical management, and routine prophylaxis.
| Attribute |
ReFacto / Xyntha |
| Active ingredient |
Moroctocog alfa |
| Therapeutic class |
Recombinant factor VIII |
| Disease |
Hemophilia A |
| Manufacturer |
Pfizer |
| U.S. brand |
Xyntha |
| International brand |
ReFacto AF |
| Administration |
Intravenous infusion |
| Product type |
B-domain-deleted recombinant factor VIII |
| FDA pathway |
Biologics license application |
| Typical commercial use |
Prophylaxis, on-demand treatment, surgical control |
| Principal competitors |
Advate, Eloctate, Esperoct, Jivi, Adynovate, Hemlibra, Altuviiio |
ReFacto was developed by Genetics Institute and Wyeth, later acquired by Pfizer. The original ReFacto product used a manufacturing process that did not include human albumin in the final formulation. ReFacto AF was introduced with manufacturing and formulation changes, including a sucrose-based formulation and a revised manufacturing process intended to improve product consistency and viral-safety controls. The U.S. product is known as Xyntha rather than ReFacto AF. [1][2]
What is the FDA regulatory status of ReFacto and Xyntha?
Xyntha is an FDA-approved recombinant factor VIII biologic. ReFacto AF has been authorized in multiple non-U.S. markets, including the European Union, subject to local marketing status and supply decisions.
The product’s regulatory position is mature:
- The original ReFacto product received U.S. approval in the late 1990s.
- Xyntha received U.S. approval in 2008.
- The FDA label covers control and prevention of bleeding episodes, perioperative management, and routine prophylaxis in hemophilia A.
- Xyntha is not a small-molecule drug approved under an abbreviated new drug application.
- Substitution through a conventional generic pathway is unavailable.
FDA labeling identifies inhibitor development as a significant clinical risk associated with factor VIII replacement. Patients with inhibitors may require bypassing agents or non-factor therapies, reducing the addressable population for conventional factor VIII products. [1]
When does ReFacto lose exclusivity?
ReFacto’s original regulatory exclusivity has expired. The product is now exposed primarily to patent, manufacturing, clinical, and commercial competition rather than basic regulatory exclusivity.
For Xyntha, the 12-year reference-product exclusivity period applicable to a licensed biologic would have expired approximately 12 years after its 2008 approval. That regulatory exclusivity does not determine the full patent term and does not itself authorize biosimilar approval.
| Exclusivity category |
ReFacto / Xyntha position |
| Small-molecule NCE exclusivity |
Not applicable |
| Original biologic regulatory exclusivity |
Expired |
| U.S. Orange Book listing |
Not applicable |
| U.S. Purple Book reference product |
Relevant regulatory framework |
| Biosimilar pathway |
Available under the BPCIA |
| Patent protection |
Product and process patents may have different expiry dates |
| Current commercial barrier |
Manufacturing complexity, physician familiarity, contracts, and supply reliability |
The absence of Orange Book listings is important. Biologics are not listed in the Orange Book in the same manner as small-molecule prescription drugs. ReFacto and Xyntha therefore do not have an Orange Book patent-certification framework that would generate a conventional Paragraph IV challenge.
What patents protect ReFacto?
ReFacto has historically been protected through a combination of patents covering recombinant factor VIII constructs, host-cell production systems, purification processes, formulations, and manufacturing controls. The relevant patent estate is more complex than a single active-ingredient patent because factor VIII is a recombinant protein produced through a multistep biological process.
The principal patent categories are:
- Recombinant factor VIII molecules, including B-domain-deleted constructs.
- Mammalian-cell expression systems.
- Cell culture and protein-production methods.
- Purification and viral-clearance processes.
- Stabilized liquid or lyophilized formulations.
- Pharmaceutical compositions and dosing methods.
- Manufacturing changes associated with ReFacto AF and Xyntha.
The practical strength of the estate depends on whether claims remain active in the target jurisdiction, whether they cover the biosimilar manufacturer’s actual process, and whether claim scope survives validity challenges. Older composition claims are more likely to have expired than later process or formulation claims.
Does ReFacto have Orange Book patents?
No. ReFacto is a biologic, and its patent position is not represented through the standard Orange Book listing system. A potential competitor would evaluate FDA patent and exclusivity information, the Purple Book, public patent databases, and any applicable BPCIA patent-exchange materials.
Are there Paragraph IV challenges to ReFacto?
A conventional Paragraph IV certification does not apply to Xyntha because it is licensed as a biologic rather than approved under an NDA. A competing manufacturer would generally pursue the biosimilar pathway under section 351(k) of the Public Health Service Act, not an ANDA with a Paragraph IV certification.
Publicly visible commercial risk has therefore shifted from classic generic litigation to biosimilar development, patent negotiation, manufacturing comparability, and potential BPCIA litigation.
How strong is the ReFacto patent estate?
The patent estate is likely moderate as a barrier to direct replication but weaker as a long-term barrier to market entry.
Strengths
- Recombinant factor VIII manufacturing requires specialized cell culture and purification capabilities.
- Product comparability is technically demanding.
- Process patents can complicate biosimilar development even after composition patents expire.
- Regulatory approval requires extensive analytical characterization and clinical or immunogenicity evidence.
- Supply reliability and payer contracting favor established manufacturers.
Weaknesses
- The product has been commercially available for decades.
- Core regulatory exclusivity has expired.
- The factor VIII field has extensive prior art and multiple established production platforms.
- Competitors can avoid some claims through alternative cell lines, purification methods, formulations, or expression constructs.
- The clinical market is moving toward products that reduce infusion frequency or eliminate factor replacement.
A biosimilar challenger would not need to reproduce Pfizer’s exact manufacturing process. It would need to demonstrate high similarity and no clinically meaningful differences, while avoiding enforceable patent claims.
What generic or biosimilar entry risks exist for ReFacto?
The direct substitution risk is lower than the broader class risk. ReFacto competes against both factor VIII biosimilars and alternative hemophilia A therapies.
Biosimilar factor VIII risk
A biosimilar could compete on:
- Contract pricing.
- Hospital and specialty-pharmacy access.
- Tender markets outside the United States.
- Switching programs for stable patients.
- Supply guarantees.
- Regional government reimbursement.
Factor VIII products are biologically complex, and physicians may be cautious about switching patients with established dosing histories. That reduces the speed of erosion compared with many oral generics.
Non-factor replacement risk
Hemlibra, Roche’s subcutaneous emicizumab, has changed prophylaxis economics by reducing infusion burden and offering treatment for patients with or without inhibitors. It competes directly with routine factor VIII prophylaxis but does not replace factor VIII in every surgical or acute bleeding setting. [3]
Gene-therapy risk
Hemgenix, a gene therapy for hemophilia B, and Roctavian, a gene therapy for hemophilia A, create a longer-term substitution risk for eligible patients. Their uptake is constrained by high upfront cost, durability questions, liver monitoring, eligibility criteria, and payer controls. [4][5]
Altuviiio, an extended-half-life factor VIII product, is a more direct commercial threat because it remains within the factor replacement category while reducing infusion frequency compared with standard-half-life products. [6]
How does ReFacto compare with competing hemophilia A drugs?
| Product |
Company |
Modality |
Commercial advantage |
Pressure on ReFacto |
| ReFacto / Xyntha |
Pfizer |
Standard-half-life recombinant FVIII |
Established product and physician familiarity |
Mature product, limited differentiation |
| Advate |
Takeda |
Standard-half-life recombinant FVIII |
Long commercial history and broad use |
Direct class competition |
| Eloctate |
Bioverativ/Sanofi |
Extended-half-life FVIII |
Longer dosing interval |
Stronger prophylaxis proposition |
| Esperoct |
Novo Nordisk |
Extended-half-life FVIII |
Reduced infusion frequency |
Competes for prophylaxis patients |
| Jivi |
Bayer |
Extended-half-life FVIII |
Reduced dosing burden |
Competes for adult and adolescent patients |
| Adynovate |
Takeda |
Extended-half-life FVIII |
Longer half-life than standard products |
Encourages switching from standard FVIII |
| Hemlibra |
Roche |
Bispecific non-factor antibody |
Subcutaneous administration and broad prophylaxis use |
Major replacement risk |
| Altuviiio |
Sanofi |
Ultra-long-acting FVIII |
Extended dosing interval |
Direct premium replacement |
| Roctavian |
BioMarin |
Gene therapy |
Potential reduction in chronic factor use |
Long-term substitution risk |
ReFacto’s central disadvantage is that it is a standard-half-life product without a clear dosing or administration advantage over newer factor VIII products. Its remaining commercial value rests on installed use, physician familiarity, supply continuity, and payer access.
What is the financial trajectory of ReFacto?
Pfizer does not disclose ReFacto or Xyntha as a separate revenue line in its principal financial reporting. The product is included within broader business categories or product groupings, preventing a reliable standalone revenue calculation.
The likely trajectory has four phases:
| Period |
Commercial condition |
Financial implication |
| Initial launch and expansion |
Adoption of recombinant factor VIII over plasma-derived products |
Revenue growth |
| Mature standard-of-care phase |
Stable prophylaxis and on-demand use |
High-value but slower growth |
| Post-extended-half-life competition |
Switching to Eloctate, Esperoct, Jivi, and Adynovate |
Volume and share pressure |
| Non-factor and gene-therapy transition |
Hemlibra, Altuviiio, and gene therapies alter treatment choices |
Structural erosion risk |
ReFacto remains a high-value specialty product because hemophilia treatment is expensive and chronic. Its financial profile is constrained by the size of the hemophilia A population, the high treatment cost per patient, and the growing use of alternatives that reduce factor consumption or infusion frequency.
Pfizer’s revenue exposure is probably limited relative to its total pharmaceutical sales because the company has a diversified portfolio and does not identify ReFacto as a major standalone growth product. The lack of product-level disclosure means no defensible public estimate can be assigned to annual ReFacto revenue, gross margin, or operating profit.
What market dynamics will determine ReFacto sales?
Payer and contracting pressure
Hemophilia treatment is concentrated among specialty pharmacies, national insurers, government programs, and treatment centers. Contract discounts can materially affect net pricing even when list prices remain high.
Switching behavior
Patients stable on ReFacto may remain on therapy because of known tolerability, established dosing, and physician preference. New patients are more likely to receive extended-half-life factor VIII or non-factor prophylaxis, which gradually reduces the product’s new-start base.
Inhibitor management
Patients who develop inhibitors may move away from factor VIII. Hemlibra has expanded the treatment options for this population and reduces the strategic importance of standard-half-life factor VIII in inhibitor-positive disease.
Supply and manufacturing
The ability to maintain uninterrupted supply is commercially important. Recombinant factor VIII requires validated cell culture, purification, viral clearance, sterile filling, and cold-chain distribution. Manufacturing disruptions can cause rapid share loss because treatment centers often substitute available products.
Geographic differences
The United States has higher use of premium specialty products and rapid adoption of non-factor prophylaxis. European markets are more exposed to centralized tenders and price controls. Emerging markets may retain greater demand for established factor VIII products, but reimbursement and supply access limit market size.
What litigation and settlement risks affect ReFacto?
No major public Paragraph IV litigation framework applies to ReFacto because it is a biologic. The more relevant legal risks are:
- Patent disputes over recombinant factor VIII production.
- BPCIA litigation involving a biosimilar applicant.
- Trade-secret or process disputes involving cell culture and purification.
- Manufacturing-change disputes involving product comparability.
- Contracting disputes involving specialty distributors and payers.
- Product-liability litigation involving inhibitor development or treatment outcomes.
No major public settlement can be identified as a current market event that materially changes ReFacto’s commercial outlook. The key legal risk is a future biosimilar or process challenge rather than a conventional generic settlement.
What is the commercial outlook for ReFacto?
ReFacto is best classified as a mature, cash-generating specialty biologic with declining strategic differentiation.
The base-case outlook is gradual erosion caused by:
- Conversion to extended-half-life factor VIII.
- Expansion of Hemlibra prophylaxis.
- Selective adoption of Altuviiio.
- Long-term gene-therapy uptake.
- Price pressure in tenders and payer contracts.
- Potential biosimilar competition.
A faster-decline scenario would occur if a biosimilar obtains approval, Pfizer reduces promotional support, or supply reliability deteriorates. A stable-revenue scenario would require strong contract retention, continued physician preference, and limited switching among existing patients. A growth scenario is less likely without a reformulated or substantially differentiated version.
Key Takeaways
- ReFacto is moroctocog alfa, marketed as Xyntha in the United States and ReFacto AF in other markets.
- It is a mature recombinant factor VIII biologic with expired regulatory exclusivity.
- Orange Book and conventional Paragraph IV analysis do not apply.
- The relevant competitive framework is biosimilar entry under the BPCIA, process-patent enforcement, and commercial contracting.
- Pfizer does not disclose standalone ReFacto revenue.
- The product faces direct pressure from Eloctate, Esperoct, Jivi, Adynovate, and Altuviiio.
- Hemlibra creates the largest non-factor substitution risk.
- Gene therapies create longer-term risk but are constrained by eligibility, durability, safety monitoring, and reimbursement.
- ReFacto’s manufacturing complexity provides a meaningful entry barrier, but its standard-half-life profile limits long-term differentiation.
- The most probable financial trajectory is gradual revenue erosion with residual value from established patients, contracts, and global supply relationships.
FAQs about ReFacto market value and competition
Is ReFacto still sold?
ReFacto AF remains an established product in markets where Pfizer maintains authorization and commercial supply. The U.S. brand is Xyntha.
Is Xyntha interchangeable with Hemlibra?
No. Xyntha is intravenous factor VIII replacement. Hemlibra is a subcutaneous bispecific antibody that mimics factor VIII activity and is used for prophylaxis. They have different labels, dosing, clinical roles, and regulatory requirements.
Can a biosimilar replace ReFacto automatically?
Automatic substitution depends on FDA interchangeability status, state law, payer policy, and treatment-center practice. Biosimilar approval alone does not guarantee automatic pharmacy substitution.
Does ReFacto have a patent cliff?
Its principal regulatory exclusivity has already expired. Any remaining patent protection is more likely to involve manufacturing, formulation, or process claims than a single broad active-ingredient patent.
Is ReFacto a major Pfizer revenue driver?
No standalone figure is disclosed, and the product is not identified as a central Pfizer growth driver. Its economic contribution is likely modest relative to Pfizer’s broader pharmaceutical portfolio.
References
-
U.S. Food and Drug Administration. (2024). Xyntha prescribing information. Pfizer and FDA labeling materials.
-
European Medicines Agency. (2024). ReFacto AF: EPAR product information. European Medicines Agency.
-
Genentech, a member of the Roche Group. (2024). Hemlibra prescribing information. U.S. Food and Drug Administration.
-
BioMarin Pharmaceutical Inc. (2024). Roctavian prescribing information. U.S. Food and Drug Administration.
-
CSL Behring. (2024). Hemgenix prescribing information. U.S. Food and Drug Administration.
-
Sanofi. (2024). Altuviiio prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
Pfizer Inc. (2024). Annual report and Form 10-K. Pfizer investor relations.
